James Allison, PhD

Regental Professor and Chair of Immunology; Founding Director of the James P. Allison Institute · MD Anderson Cancer Center; James P. Allison Institute · company speakers →

James Allison, PhD, is a 2018 Nobel Laureate and a pioneer in cancer immunotherapy whose discovery of immune checkpoint blockade revolutionized oncology. By identifying how molecules like CTLA-4 inhibit T cell responses, Dr. Allison developed the first FDA-approved checkpoint inhibitor, ipilimumab—a breakthrough that enables the immune system to recognize and eradicate cancer cells. Currently the Regental Professor and Chair of Immunology at MD Anderson and Founding Director of the James P. Allison Institute, he continues to lead research into next-generation therapies. A member of the National Academies of Sciences and Medicine, his work has earned numerous prestigious honors, including the Lasker-DeBakey and Breakthrough Prizes.

Is this you? Claim this profile →